Ethnic disparities in liver transplantation

Gastroenterology and Hepatology

Volumn 7, Issue 5, 2011, Pages 302-307

  Kemmer, Nyingi ^a,b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

End stage liver disease; Ethnicity; Liver transplantation

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; DRUG METABOLIZING ENZYME; INTERLEUKIN 28B; TACROLIMUS;

AFRICAN AMERICAN; ANTIVIRAL THERAPY; ASIAN; DRUG RESPONSE; END STAGE LIVER DISEASE; ESOPHAGUS VARICES; ETHNIC DIFFERENCE; FULMINANT HEPATIC FAILURE; GRAFT REJECTION; HEALTH CARE ACCESS; HEALTH CARE DISPARITY; HEALTH INSURANCE; HEPATITIS B; HEPATITIS C; HISPANIC; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; ORGAN DONOR; PATIENT REFERRAL; PHARMACOGENETICS; POPULATION GENETICS; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 79957938132     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Stinson FS, Grant BF, Dufour MC. The critical dimension of ethnicity in liver cirrhosis mortality statistics. Alcohol Clin Exp Res. 2001;25:1181-1187. (Pubitemid 32758470)
2. Lucey MR, Brown KA, Everson GT, et al. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg. 1997;3:628-637. (Pubitemid 27498478)
3. Nguyen GC, Segev DL, Thuluvath PJ. Racial disparities in the management of hospitalized patients with cirrhosis and complications of portal hypertension: a national study. Hepatology. 2007;45:1282-1289. (Pubitemid 46775792)
4. Sanyal AJ, Fontana RJ, Di Bisceglie AM, et al; HALT-C Trial Group. The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. Gastrointest Endosc. 2006;64:855-864. (Pubitemid 44829826)
5. Fontana RJ, Sanyal AJ, Mehta S, et al. Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C trial. Am J Gastroenterol. 2006;101:983-992. (Pubitemid 43725311)
6. Fontana RJ, Sanyal AJ, Ghany MG, et al; HALT-C Trial Group. Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. Gastroenterology. 2010;138:2321-2331, 2331.e1-2331.e2.
7. Jamal MM, Samarasena JB, Hashemzadeh M. Decreasing in-hospital mortality for oesophageal variceal hemorrhage in the USA. Eur J Gastroenterol Hepatol. 2008;20:947-955.
8. Julapalli VR, Kramer JR, El-Serag HB; American Association for the Study of Liver Diseases. Evaluation for liver transplantation: adherence to AASLD referral guidelines in a large Veterans Affairs center. Liver Transpl. 2005;11:1370-1378. (Pubitemid 43071586)
9. Eckhoff DE, McGuire BM, Young CJ, et al. Race: a critical factor in organ donation, patient referral and selection, and orthotopic liver transplantation? Liver Transpl Surg. 1998;4:499-505. (Pubitemid 28496253)
10. Kemmer N, Zacharias V, Kaiser TE, Neff GW. Access to liver transplantation in the MELD era: role of ethnicity and insurance. Dig Dis Sci. 2009;54:1794-1797.
11. Moylan CA, Brady CW, Johnson JL, Smith AD, Tuttle-Newhall JE, Muir AJ. Disparities in liver transplantation before and after introduction of the MELD score. JAMA. 2008;300:2371-2378.
12. Agency for Healthcare Research and Quality Web site. US Department of Health and Human Services. http://www.ahrq.gov.
13. Bryce CL, Angus DC, Arnold RM, et al. Sociodemographic differences in early access to liver transplantation services. Am J Transplant. 2009;9:2092-2101.
14. Volk ML, Choi H, Warren GJ, Sonnenday CJ, Marrero JA, Heisler M. Geographic variation in organ availability is responsible for disparities in liver transplantation between Hispanics and Caucasians. Am J Transplant. 2009;9:2113-2118.
15. Reid AE, Resnick M, Chang Y, Buerstatte N, Weissman JS. Disparity in use of orthotopic liver transplantation among blacks and whites. Liver Transpl. 2004;10:834-841. (Pubitemid 38979251)
16. Mathur AK, Schaubel DE, Gong Q, Guidinger MK, Merion RM. Racial and ethnic disparities in access to liver transplantation. Liver Transpl. 2010;16:1033-1040.
17. Luan FL, Kommareddi M, Cibrik DM, Samaniego M, Ojo AO. Influence of recipient race on the outcome of simultaneous pancreas and kidney transplantation. Am J Transplant. 2010;10:2074-2081.
18. Fan PY, Ashby VB, Fuller DS, et al. Access and outcomes among minority transplant patients, 1999-2008, with a focus on determinants of kidney graft survival. Am J Transplant. 2010;10(4 pt 2):1090-1107.
19. Allen JG, Weiss ES, Arnaoutakis GJ, et al. The impact of race on survival after heart transplantation: an analysis of more than 20,000 patients. Ann Thorac Surg. 2010;89:1956-1963; discussion 1963-1964.
20. Nair S, Eustace J, Thuluvath PJ. Effect of race on outcome of orthotopic liver transplantation: a cohort study. Lancet. 2002;359:287-293. (Pubitemid 34119291)
21. Ananthakrishnan AN, Saeian K. Racial differences in liver transplantation outcomes in the MELD era. Am J Gastroenterol. 2008;103:901-910. (Pubitemid 351501120)
22. Thuluvath PJ, Guidinger MK, Fung JJ, Johnson LB, Rayhill SC, Pelletier SJ. Liver transplantation in the United States, 1999-2008. Am J Transplant. 2010;10(4 pt 2):1003-1019.
23. Neff GW, Kemmer N, Kaiser T, Zacharias V, Majoras N, Safdar K. Outcomes in adult and pediatric liver transplantation among various ethnic groups. Transplant Proc. 2007;39:3204-3206. (Pubitemid 350251498)
24. Roberts MS, Angus DC, Bryce CL, Valenta Z, Weissfeld L. Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database. Liver Transpl. 2004;10:886-897. (Pubitemid 38979259)
25. Muir AJ, Bornstein JD, Killenberg PG; Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004;350:2265-2271. (Pubitemid 38669209)
26. Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006;131:470-477. (Pubitemid 44142464)
27. Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zein NN. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy. Liver Transpl. 2008;14:53-58. (Pubitemid 351167989)
28. Pang PS, Kamal A, Glenn JS. The effect of donor race on the survival of black Americans undergoing liver transplantation for chronic hepatitis C. Liver Transpl. 2009;15:1126-1132.
29. Bzowej N, Han S, Degertekin B, et al; National Institutes of Health Hepatitis B Virus Orthotopic Liver Transplantation Study Group. Liver transplantation outcomes among Caucasians, Asian Americans, and African Americans with hepatitis B. Liver Transpl. 2009;15:1010-1020.
30. Kim WR, Poterucha JJ, Kremers WK, Ishitani MB, Dickson ER. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl. 2004;10:968-974. (Pubitemid 39232749)
31. Charlton MR, Thompson A, Veldt BJ, et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology. 2011;53:317-324.
32. Min DI, Lee M, Ku YM, Flanigan M. Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. Clin Pharmacol Ther. 2000;68:478-486.
33. Isaacs RB, Nock SL, Spencer CE, et al. Racial disparities in renal transplant outcomes. Am J Kidney Dis. 1999;34:706-712. (Pubitemid 29473059)
34. Dirks NL, Huth B, Yates CR, Meibohm B. Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. Int J Clin Pharmacol Ther. 2004;42:701-718. (Pubitemid 39625130)
35. Andrews PA, Sen M, Chang RW. Racial variation in dosage requirements of tacrolimus. Lancet. 1996;348:1446. (Pubitemid 26395245)
36. Mancinelli LM, Frassetto L, Floren LC, et al. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther. 2001;69:24-31. (Pubitemid 32108668)
37. Nagashima N, Watanabe T, Nakamura M, Shalabi A, Burdick JF. Decreased effect of immunosuppression on immunocompetence in African Americans after kidney and liver transplantation. Clin Transplant. 2001;15:111-115. (Pubitemid 32229799)
38. Maggard M, Goss J, Ramdev S, Swenson K, Busuttil RW. Incidence of acute rejection in African-American liver transplant recipients. Transplant Proc. 1998;30:1492-1494. (Pubitemid 28309659)
39. Zahir H, McCaughan G, Gleeson M, Nand RA, McLachlan AJ. Factors affecting variability in distribution of tacrolimus in liver transplant recipients. Br J Clin Pharmacol. 2004;57:298-309. (Pubitemid 38296993)
40. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002;54:1271-1294. (Pubitemid 35284253)
41. MacPhee IA, Fredericks S, Tai T, et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant. 2004;4:914-919. (Pubitemid 38745590)